Resistant arterial hypertension has been defined as a condition where a patient is being treated with an antihypertensive regimen with ≥ 4 drugs or ≥ 3 drugs that include a diuretic and still has blood pressure figures ≥ 140/90 mmHg. Given that the prevalence of resistant arterial hypertension is high, clinicians should be aware of its potential risk of not handling this condition. This review aims to discuss contributors and clinical recommendations to help clinicians better understand and treat resistant arterial hypertension within all care settings. We also demonstrate data from randomized placebo-controlled trials and conclude that renal denervation significantly reduces ambulatory and office blood pressure. Moreover, it was similar between patients on and off background antihypertensive medications. Furthermore, a novel therapy named baroreceptor stimulation therapy has shown promising data in both experimental and clinical experiments to handle resistant arterial hypertension. Both approaches may be highly relevant in patients who are intolerant to medications.
CITATION STYLE
Parcero-Valdés, J. J., & Díaz-y-Díaz, E. (2022). Impacto de las terapias alternativas en el tratamiento de la hipertensión arterial sistémica resistente. Cardiovascular and Metabolic Science, 33(S3), 233–237. https://doi.org/10.35366/105189
Mendeley helps you to discover research relevant for your work.